







an Open Access Journal by MDPI

# Advances and Challenges in the Diagnosis and Treatment of Urological Malignancies

Guest Editors:

#### Dr. Bartosz Małkiewicz

University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland

## Prof. Dr. Jakub Dobruch

Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland

Deadline for manuscript submissions:

closed (30 June 2023)

## **Message from the Guest Editors**

The incidence of urological tumors has increased significantly over the past 40 years, and prostate cancer is the second most common malignancy among men. Even if in most cases the initial treatment is curative, a certain number of patients experience a poor course of disease with local or distant recurrence, and require further treatment, which significantly worsens their quality of life.

Over the past two decades, great efforts have been made to improve diagnosis and treatment outcomes. Molecular biomarkers have been investigated and introduced into clinical practice, and new pathological and clinical classifications have been proposed to account for tumor behavior and risk of disease recurrence. At the same time, new surgical and pharmacological approaches have been developed to improve treatment outcomes.

Nevertheless, many issues remain a matter of debate regarding accurate diagnosis, targeted therapy and multidisciplinary management.

This Special Issue of *Cancers* will cover all aspects of urological cancers, original research, systematic reviews and meta-analyses are all welcome.













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

# **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**